Skip to main content

Table 2 Immunologic and hematologic features in pediatric SLE according to myositis status

From: High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort

 

Myositis group, n(%)

Non-myositis group, n(%)

Entire cohort,

n(%)

ANA

17

(100)

38

(100)

55

(100)

ANA pattern:

      

   Speckled

11

(65)

19

(50)

30

(55)

   Homogeneous

5

(29)

16

(42)

21

(38)

   Nucleolar

1

(5.9)

0

(0)

1

(1.8)

   Dual

0

(0)

3

(7.9)

3

(5.5)

Sm a

15

(88)

21/35

(60)

36/52

(69)

dsDNA b

10

(59)

34

(89)

44

(80)

RNP c

16

(94)

20/35

(57)

36/52

(69)

Scl-70

0/16

(0)

1/27

(3.7)

1/43

(2.3)

Ro/SS-A

8

(47)

16/32

(50)

24/49

(49)

La/SS-B

5

(29)

7/32

(22)

12/49

(24)

RF

3/9

(33)

6/21

(29)

9/30

(30)

Low C3

4

(24)

15

(39)

19

(35)

Low C4

7

(41)

24

(63)

31

(56)

Low CH50

2/5

(40)

12/20

(60)

14/25

(56)

β2-glycoprotein I

3/14

(21)

4/30

(13)

7/44

(16)

aCL (IgG and/or IgM)

3/14

(21)

17/29

(59)

20/43

(47)

LA

2/13

(15)

7/32

(22)

9/45

(20)

Increased PTT

5/14

(36)

6/32

(19)

11/46

(24)

Reactive RPR

2/6

(33)

4/11

(36)

6/17

(35)

  1. Myositis group, n = 17; non-myositis group, n = 38; entire cohort, n = 55. aNear statistically significant direct association with myositis (p = 0.06). bStatistically significant inverse association with myositis (p = 0.02). cStatistically significant direct association with myositis (p = 0.009).
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096